BHMT Genotype

If you have ever wondered why two people eating the same diet end up with different homocysteine levels, or why your sister had a complicated pregnancy on identical prenatal vitamins, part of the answer can sit inside a single gene called BHMT (betaine-homocysteine methyltransferase). This test reads the version of BHMT you inherited and shows whether you carry common variants that change how efficiently your body recycles homocysteine using betaine, a nutrient found in beets, spinach, and wheat germ.

BHMT genotype is a research-grade genetic marker. Carrying a variant does not guarantee you will develop any specific condition, and most variants exert their effect only when combined with low folate, low choline, certain medications, or other genetic background. Think of it as one piece in a larger methylation puzzle, not a verdict.

What BHMT Actually Does

BHMT is an enzyme made mostly in your liver and kidneys, where it can account for up to half of homocysteine recycling in the liver. Its job is to take homocysteine, a building block your body needs to recycle, and convert it back into methionine using betaine as a chemical helper. This pathway runs alongside the more familiar folate-and-B12 route. The product of this reaction is a molecule called dimethylglycine (DMG).

The most studied variant is BHMT c.716G greater than A, also called R239Q or rs3733890. In a large population study of adults, each copy of the A allele was linked to lower blood levels of DMG, the direct product of the BHMT reaction. A separate pregnancy study of 612 women confirmed the same pattern, with the A allele tracking with lower DMG during pregnancy. These are subtle, pathway-specific shifts rather than dramatic disruptions of methylation.

Heart Disease Risk

In a study of 504 adults who underwent coronary angiography, the QQ form of the R239Q variant appeared more often in people with no or mild coronary artery disease (11 percent) than in those with significant artery narrowing (6 percent). The authors interpreted this as a possible protective effect of the Q allele, with an odds ratio of 0.48, though the confidence interval (0.21 to 1.06) crossed 1.0, so the finding warrants more confirmation. Plasma homocysteine itself did not differ meaningfully by genotype in that study, which means whatever protection exists is probably not mediated through a simple homocysteine drop.

For early-onset ischemic stroke, an Italian study of 1,622 young adults found that a different BHMT variant, rs10037045, and certain BHMT haplotype combinations remained independent risk factors for stroke even after adjusting for traditional cardiovascular risk factors. The effect was modest but did not disappear once smoking, blood pressure, and cholesterol were accounted for.

Pregnancy and Birth Outcomes

BHMT variants show up most clearly in pregnancy research. The pattern is consistent: genotype matters more when nutrition or other exposures are imperfect.

What this means for you: if you are planning a pregnancy or already pregnant, the practical takeaway is not that a BHMT variant dooms anything. It is that adequate folate and choline intake, supported by prenatal supplementation and food sources like eggs and leafy greens, appears to neutralize most of the measurable risk these variants confer.

Two additional pregnancy findings round out the picture. A conference abstract reporting on 270 Chinese women suggested that the BHMT rs3733890 variant interacted with low maternal choline intake to raise the risk of preterm birth, though this preliminary finding has not yet appeared in a full peer-reviewed publication. And a large population-based study found that maternal SSRI use during pregnancy combined with certain BHMT variants (rs492842 and rs542852) was associated with roughly twice the risk of congenital heart defects in offspring.

Cancer and Other Conditions

In the Nurses' Health Study analysis of 1,113 women, the BHMT R239Q variant interacted with dietary folate, methionine, and alcohol intake to modify colorectal adenoma risk. The variant alone was not a strong driver, but it shifted risk in people whose diet was already low in methyl donors. A meta-analysis of cleft lip and palate found that the CC genotype of BHMT rs3797546 was significantly associated with increased risk of non-syndromic oral clefts. A separate large analysis of cleft cases and controls identified an interaction between BHMT and DMGDH, a related metabolic gene, supporting the gene-gene interaction theme that runs through BHMT research.

Why Context Matters More Than the Genotype Itself

A consistent thread across the BHMT literature is that variants rarely act alone. Their effect depends on folate status, choline and betaine intake, body weight, medication exposure (particularly SSRIs during pregnancy), smoking, and which version of related genes (MTHFR, MTR, MTRR, DMGDH) you also carry. This is why carrying a BHMT variant is not a diagnosis. It is a context-dependent risk modifier.

What this means for you: the same variant can be functionally invisible in one person and clinically relevant in another, depending on lifestyle and nutrition. The actionable response to a variant result is almost always about optimizing the modifiable side of the equation, not about the gene itself.

Your Result Is Permanent

BHMT genotype does not change. The version of the gene you inherited at conception is the version you will carry your entire life, so this test is one-time. You do not retest the gene itself. What you do retest, when clinically appropriate, are the downstream markers that BHMT activity influences: homocysteine, folate, B12, and choline-related metabolites. These tell you whether the methylation system as a whole is working well, regardless of your genotype. Routine annual screening of these markers based on BHMT genotype alone is not part of established clinical guidelines, so testing frequency is best discussed with your clinician based on your overall risk profile.

If you make changes based on this result, such as adding choline or betaine, increasing leafy greens, or starting a methylated B-vitamin complex, retest those downstream metabolite levels in 3 to 6 months to see whether your interventions are landing.

When Results Can Be Misleading

• Variant panel coverage: the assay only detects the specific BHMT variants it is designed to look for. A result showing none of the tested variants does not rule out other rare BHMT changes that the panel was not built to find.
• Ethnic-specific allele frequencies: several BHMT variants have very different frequencies across populations. A 'positive' result for an allele common in one ancestry group may carry different research-backed risk than the same allele in another group.
• Pathway membership is not destiny: carrying a BHMT variant does not mean your one-carbon metabolism is broken. The studies that show clinical associations almost always require an additional factor, such as low folate, low choline, obesity, or SSRI exposure, before the variant translates into measurable risk.
• Direct-to-consumer chip vs. clinical-grade calls: if you have seen a 23andMe-style raw data report flag a BHMT variant, the call quality is generally lower than a clinical assay. Confirm any actionable finding with a clinical-grade test before acting on it.

What an Unexpected Result Should Prompt You to Do

A BHMT variant call is not a stand-alone clinical event. It is the starting point for a slightly more aggressive monitoring plan. Pair the result with measurement of homocysteine, folate, B12, and (if available) choline metabolites to see whether the pathway is functioning normally despite the variant. If you are planning a pregnancy and carry a risk variant, the most concrete step backed by the data is to ensure consistent folate supplementation well before conception, since this is where the variants' effects most often emerge.

If your homocysteine is elevated alongside a BHMT variant, that combination strengthens the case for working with a clinician familiar with methylation biology to investigate B-vitamin status and consider supplementation. If you have a family history of neural tube defects, congenital heart defects, or early cardiovascular disease, share your BHMT result with biological relatives. They share roughly half your DNA on average, and the information may inform their own preconception planning or cardiovascular workup.